Royalty Report: Drugs, Arthritis, Antibody – Collection: 289246

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 7

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 7

Primary Industries

  • Drugs
  • Arthritis
  • Antibody
  • Therapeutic
  • Disease
  • Drug Discovery
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 289246

License Grant
Licensor grants the Licensee of China an exclusive, non-transferable, perpetual license in the field of Therapeutic usage in order to develop and conduct clinical trials to achieve Chinese FDA (SFDA) approval of the rabbit anti-TNFalpha monoclonal antibody compounds. Under these rights, Licensor grants both the manufacturing and distribution rights of anti-TNFalpha monoclonal antibody therapeutics covered under the intellectual properties rights owned by Licensor.
License Property
Licensor utilizes a proprietary and patented technology in the development and production of Rabbit Monoclonal Antibodies (RabMAb technology).

Licensor has developed a panel of 50 novel anti-TNFalpha rabbit monoclonal antibodies that are highly potent compared with Remicade and Humira in in-vitro assays.

Licensor will provide Humanized Rabbit anti-TNFalpha monoclonal antibodies to Licensee.

Field of Use
The field is for commercializing anti-TNFalpha monoclonal antibodies to be used as therapeutic agents.  Anti-TNFalpha therapies are effective in treating Rheumatoid arthritis, Psoriasis, Psoriatic arthritis, Ankylosing spondylis and Crohns diseases.

IPSCIO Record ID: 289253

License Grant
The Licensor of China grants the right to use all intellectual properties generated during the development of the Therapeutic Product under this agreement.
License Property
The developments will be related to Anti-TNFalpha therapies.

Tumor necrosis factor a (TNF) is one of the key chemical messengers that help regulate the inflammatory process and plays an important role in the underlying mechanisms of conditions such as rheumatoid arthritis, psoriasis, and many other inflammatory disorders. When the body produces too much TNF, it overwhelms the immune system’s ability to control inflammation of the joints or of psoriasis-affected skin areas. The TNF inhibitors are molecules that disrupt the TNF function by blocking the binding of TNF to the TNF receptors. Blockage of these receptors can result in a significant reduction in inflammatory activity and reduce symptoms, inhibit the progression of structural damage, and improve physical function in patients with moderate to severe rheumatoid arthritis.

Field of Use
The field is for commercializing anti-TNFalpha monoclonal antibodies to be used as therapeutic agents.

IPSCIO Record ID: 26092

License Grant
The Compny announced that it had reached a settlement agreement.
License Property
Humira(R) is licensed to Licensee, is the first Licensor-derived antibody to be approved for marketing. It was isolated and optimized in collaboration with Licensee and has been approved for marketing as a treatment for rheumatoid arthritis (RA) in 57 countries, and for Psoriatic arthritis and early RA in some European countries and the US.

Humira (adalimumab) is a fully human anti-TNFa monoclonal antibody, isolated and optimized by Licensor in collaboration with Licensee and now approved for marketing as a treatment for rheumatoid arthritis or RA, early RA and Psoriatic arthritis.  Humira (adalimumab) is Licensor's only marketed product, approved as a rheumatoid arthritis treatment.

IPSCIO Record ID: 289928

License Grant
The Company entered a joint venture with Chinese Licensor to further develop and commercialize ONS-3010 with Licensor in the agreed countries.
License Property
The Phase I ONS-3010 trial demonstrated pharmacokinetic (PK) bioequivalence on the primary and secondary endpoints for the biosimilar candidate and the US and EU originator product (Humira).

ONS-3010 is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.

Humira, the reference product for ONS-3010, is a subcutaneous injectable mAb that binds to tumor necrosis factor alpha, or TNFa. TNFa belongs to a family of pro-inflammatory cytokines, or soluble protein mediators, that are key initiators of immune-mediated inflammation in many different diseases, such as rheumatoid arthritis, psoriatic arthritis, psoriasis, ankylosing spondylitis, Crohn’s disease and ulcerative colitis. Several biologic agents, including Humira, have been developed to inhibit the inflammatory activity of TNFs in the context of these diseases and are collectively referred to as the anti-TNF class of therapeutics.

Field of Use
Humira is used to treat many inflammatory conditions in adults, such as ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, and a skin condition called hidradenitis suppurativa.

IPSCIO Record ID: 273384

License Grant
Sellers hereby grants to Buyer an exclusive, limited to the Anthrax Field, worldwide, perpetual license under the Technology to Develop and Commercialize Products intended for use in the Anthrax Field, with the right to grant sublicenses.
License Property
Technology means Know-How or intellectual property owned, or licensed, by Seller reasonably necessary or useful in connection with the development or commercialization of pharmaceutical products incorporating human monoclonal antibodies.

The AVP Anthrax Patents constitute all patents and patent applications owned by Sellers necessary or useful for the exploitation of the Product and the conduct of the Product Line Operations.

Licensed Product means the Product as licensed or approved by any applicable Regulatory Authority or any product Developed or Commercialized under a sublicense of the rights granted under the Asset License in this Agreement.

Field of Use
Buyer received a limited exclusive license to use Sellers's proprietary Xenerexâ„¢ Technology platform to develop future human monoclonal antibodies targeted against Bacillus anthracis.

IPSCIO Record ID: 245716

License Grant
The Swiss Licensor grants to the UK Licensee a worldwide, exclusive license, including the right to grant sublicenses, under the Licensed Patents, for Licensee and its Affiliates to research, develop, make, have made, use, offer for sale, sell, have sold and import Licensed Products for any and all uses in the Field in the Territory.
License Property
The nti-IL6R antibodies marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. The Licensee intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases.
Field of Use
Field means any and all uses including all therapeutic uses.  Licensed IP includes the nti-IL6R antibodies for a range of inflammatory conditions including rheumatoid arthritis.

Licensee desires to obtain an exclusive license to patents owned or controlled by Licensor, a sublicense to certain patents licensed from Bristol-Myers Squibb Company (“BMS”), along with any associated know-how, biologic materials, clinical data or other technology relating to IL-6 receptor monoclonal antibodies (identified as NI-1201), and their use in order to research, develop and commercialize products and services.

IPSCIO Record ID: 231728

License Grant
The Licensor granted the Bermudan Licensee an exclusive, sublicensable, worldwide license to certain intellectual property rights to make, use, develop and commercialize mavrilimumab. a human monoclonal antibody for the treatment of rheumatoid arthritis.
License Property
The Licensor also granted reference rights to relevant manufacturing and regulatory documents and existing supply of mavrilimumab drug substance and product.
Field of Use
The Bermudan Licensee is obligated to use commercially reasonable efforts to develop and commercialize the licensed products.  The investigational drug may be used as a rheumatoid arthritis treatment.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.